研究者詳細 - 國定　俊之

論文 - 國定　俊之

分割表示 556 件中 161 - 180 件目／全件表示 >>

浸潤性軟部肉腫における放射線療法の治療効果の検討

畑利彰, 藤原智洋, 吉田晶, 近藤宏也, 近藤彩奈, 片山晴喜, 佐藤浩平, たき平将太, 中田英二, 国定俊之, 尾崎敏文

日本整形外科学会雑誌 96 ( 6 ) S1365 - S1365 2022年6月

骨盤周囲深部発生軟部肉腫の治療成績

片山晴喜, 藤原智洋, 国定俊之, 中田英二, 尾崎敏文

日本整形外科学会雑誌 96 ( 6 ) S1363 - S1363 2022年6月

80歳以上の超高齢軟部肉腫患者の治療における老年学的因子の意義

近藤彩奈, 藤原智洋, 吉田晶, 片山晴喜, 畑利彰, 佐藤浩平, たき平将太, 近藤宏也, 中田英二, 国定俊之, 尾崎敏文

日本整形外科学会雑誌 96 ( 6 ) S1298 - S1298 2022年6月

ナビゲーション支援手術は補助療法の効果を期待しにくい骨盤軟骨肉腫の腫瘍学的予後を改善させるか

藤原智洋, 金内洋一, 津田祐輔, Stevenson Jonathan, Parry Michael, Grimer Robert, Jeys Lee, 中田英二, 国定俊之, 尾崎敏文

日本整形外科学会雑誌 96 ( 6 ) S1288 - S1288 2022年6月

転移性骨腫瘍(切迫骨折の治療) 大腿骨近位部転移性骨腫瘍に対する手術療法

佐藤浩平, 依光正則, 福岡史朗, 畑利彰, 近藤宏也, 上原健敬, 中田英二, 国定俊之, 野田知之, 尾崎敏文

骨折 44 ( Suppl. ) S70 - S70 2022年6月

術前肺がん患者のサルコペニア・がんロコモと術後合併症の関連性

堅山佳美, 千田益生, 中田英二, 濱田全紀, 国定俊之, 藤原智洋, 尾崎敏文

The Japanese Journal of Rehabilitation Medicine ( 特別号 ) S35 - S35 2022年5月

術前肺がん患者のサルコペニア・がんロコモと術後合併症の関連性

堅山佳美, 千田益生, 中田英二, 濱田全紀, 国定俊之, 藤原智洋, 尾崎敏文

The Japanese Journal of Rehabilitation Medicine ( 特別号 ) S35 - S35 2022年5月

脊椎転移に対する放射線治療の有用性

中田英二, 国定俊之, 藤原智洋, 尾崎敏文

The Japanese Journal of Rehabilitation Medicine ( 特別号 ) S621 - S621 2022年5月

骨軟部腫瘍患者の術前ストレススクリーニング

伊勢真人, 藤原智洋, 堅山佳美, 中田英二, 濱田全紀, 國定俊之, 千田益生, 尾崎敏文, 田島文博

The Japanese Journal of Rehabilitation Medicine ( 特別号 ) S629 - S629 2022年5月

A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610

Hiroshi Urakawa, Akihito Nagano, Ryunosuke Machida, Kazuhiro Tanaka, Tomoko Kataoka, Yuta Sekino, Yoshihiro Nishida, Mitsuru Takahashi, Toshiyuki Kunisada, Masanori Kawano, Yukihiro Yoshida, Tatsuya Takagi, Kenji Sato, Toru Hiruma, Hiroshi Hatano, Satoshi Tsukushi, Akio Sakamoto, Toshihiro Akisue, Koji Hiraoka, Toshifumi Ozaki

JAPANESE JOURNAL OF CLINICAL ONCOLOGY 2022年4月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：OXFORD UNIV PRESS

Though JCOG1610 gave only descriptive results, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect in terms of relapse-free survival.Objectives The aim of JCOG1610 (randomized controlled phase III trial) was to confirm the superiority of preoperative denosumab to curettage with adjuvant local therapy for patients with giant cell tumor of bone without possible post-operative large bone defect. Methods The primary endpoint was relapse-free survival and the total sample size was set at 106 patients. Patient accrual began in October 2017. However, the accrual was terminated in December 2020 due to a recommendation from the Data and Safety Monitoring Committee because of poor patient accrual. Now, we report the descriptive results obtained in this study. Results A total of 18 patients had been registered from 13 Japanese institutions at the time of termination on December 2020. Eleven patients were assigned to Arm A (curettage and adjuvant local therapy) and 7 to Arm B (preoperative denosumab, curettage and adjuvant local therapy). Median follow-up period was 1.6 (range: 0.5-2.8) years. Protocol treatment was completed in all but one patient in Arm A who had a pathological fracture before surgery. All patients in Arm B were treated with five courses of preoperative denosumab. Relapse-free survival proportions in Arm A and B were 90.0% (95% confidence interval: 47.3-98.5) and 100% (100-100) at 1 year, and 60.0% (19.0-85.5) and 62.5% (14.2-89.3) at 2 years, respectively [hazard ratio (95% confidence interval): 1.51 (0.24-9.41)]. Conclusion In terms of relapse-free survival, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect.

DOI： 10.1093/jjco/hyac071

Web of Science

researchmap

骨軟部腫瘍患者におけるがん遺伝子パネル検査によるgermline findingの同定

中田英二, 藤原智洋, 国定俊之, 二川摩周, 平沢晃, 尾崎敏文

中部日本整形外科災害外科学会雑誌 65 ( 春季学会 ) 125 - 125 2022年4月

Japanese Orthopaedic Association (JOA) clinical practice guidelines on the management of soft tissue tumors 2020 - Secondary publication.

Akira Kawai, Nobuhito Araki, Keisuke Ae, Toru Akiyama, Toshifumi Ozaki, Hirotaka Kawano, Toshiyuki Kunisada, Minako Sumi, Shunji Takahashi, Kazuhiro Tanaka, Satoshi Tsukushi, Norifumi Naka, Yoshihiro Nishida, Mitsuru Miyachi, Norio Yamamoto, Akihiko Yoshida, Tsukasa Yonemoto, Masahiro Yoshida, Shintaro Iwata

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 27 ( 3 ) 533 - 550 2022年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: These clinical practice guidelines are intended to provide recommendations based on the best evidence obtained to date on key issues in clinical practice to improve the prognosis, diagnostic and therapeutic processes for patients with soft tissue tumors. METHODS: The Guidelines Development Committee and Systematic Review Committee were composed of a multidisciplinary team of specialists who play an important role in soft tissue tumor care. Clinical questions (CQs) were determined by choosing key decision-making points based on Algorithms for the diagnosis and treatment of soft tissue tumors. The guidelines were developed according to the "Medical Information Network Distribution Service (Minds) Handbook for Clinical Practice Guideline Development 2014" and "Minds Manual for Clinical Practice Guideline Development 2017." Recommendation strength was rated on two levels and the strength of evidence was rated on four levels. The recommendations were decided based on agreement by 70% or more voters. RESULTS: Twenty-two CQs were chosen by the Guidelines Development Committee. The Systematic Review Committee reviewed the evidence concerning each CQ, a clinical value judgment was added by experts, and the text of each recommendation was determined. CONCLUSION: We established 22 CQs and recommendations for key decision-making points in the diagnosis and treatment of soft tissue tumors according to the Minds Clinical Practice Guideline development methods. We hope that these guidelines will assist the decision-making of all medical staff engaged in the treatment and diagnosis of soft tissue tumors, and eventually lead to improved soft tissue tumor care in the country.

DOI： 10.1016/j.jos.2021.11.023

PubMed

researchmap

がんゲノム中核拠点病院における、がん遺伝子パネルで同定されたGermline Findingsに対する診療システムの構築

中田英二, 二川摩周, 国定俊之, 藤原智洋, 平沢晃, 尾崎敏文

日本整形外科学会雑誌 96 ( 2 ) S439 - S439 2022年3月